Skip to main content
Erschienen in: Clinical and Translational Oncology 3/2020

06.06.2019 | Research Article

Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma

verfasst von: Shan-Shan Wu, Quan-Yuan Shan, Wen-Xuan Xie, Bin Chen, Yang Huang, Yu Guo, Xiao-Yan Xie, Ming-De Lu, Bao-Gang Peng, Ming Kuang, Shun-Li Shen, Wei Wang

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hepatitis B core antibody (HBcAb) positivity is regarded as a sensitive marker for occult and prior hepatitis B virus (HBV) infection. However, the prognosis of patients with HBcAb-positive in non-B, non-C hepatocellular carcinoma (NBNC-HCC) remains unclear. The study aimed to compare the clinicopathological characteristics of patients with HBcAb-positive NBNC-HCC to those with overt HBV (hepatitis B surface antigen positive) HCC.

Methods

306 HCC patients underwent hepatectomy were divided into two groups: an overt HBV-HCC group and HBcAb-positive NBNC-HCC group. Then patients were analyzed using propensity score matching (PSM) to reduce selection bias. Clinicopathological characteristics and survival outcomes were compared between the two groups. Univariate and multivariate analysis for risk factors were also evaluated.

Results

HBcAb-positive NBNC-HCC group showed comparable survival outcomes to the overt HBV-HCC group (3-year overall survival rates 66% vs 62%, 69% vs 53%; 3-year recurrence-free survival rates 49% vs 40%, 47% vs 37%; P > 0.05) before and after PSM. Patients with HBcAb-positive NBNC-HCC were older, had more complications, higher proportions of vascular invasion, and larger tumor sizes but lower proportions of cirrhosis, elevated alanine aminotransferase and prothrombin time.

Conclusions

HBcAb-positive NBNC-HCC group had more advanced tumors, but their prognosis was relatively comparable to that of the other group. Therefore, we believe that screening is also necessary in HBcAb-positive patients for early detection of HCC, especially in the elderly.
Literatur
1.
Zurück zum Zitat Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer. 2018;7(3):235–60. Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer. 2018;7(3):235–60.
2.
Zurück zum Zitat Wu M, Tan H, Gao F, Hai J, Ning P, Chen J et al. Predicting the grade of hepatocellular carcinoma based on non-contrast-enhanced MRI radiomics signature. Eur Radiol. 2018. Wu M, Tan H, Gao F, Hai J, Ning P, Chen J et al. Predicting the grade of hepatocellular carcinoma based on non-contrast-enhanced MRI radiomics signature. Eur Radiol. 2018.
3.
Zurück zum Zitat Li T, Qin LX, Gong X, Zhou J, Sun HC, Qiu SJ, et al. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer. 2013;119(1):126–35.CrossRef Li T, Qin LX, Gong X, Zhou J, Sun HC, Qiu SJ, et al. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer. 2013;119(1):126–35.CrossRef
4.
Zurück zum Zitat Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, et al. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. Annal Surg. 2014;259(2):336–45.CrossRef Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, et al. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. Annal Surg. 2014;259(2):336–45.CrossRef
5.
Zurück zum Zitat Lee SS, Jeong SH, Byoun YS, Chung SM, Seong MH, Sohn HR, et al. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer. 2013;13:335.CrossRef Lee SS, Jeong SH, Byoun YS, Chung SM, Seong MH, Sohn HR, et al. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer. 2013;13:335.CrossRef
6.
Zurück zum Zitat Yuan JM, Govindarajan S, Arakawa K, Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the US. Cancer. 2004;101(5):1009–177.CrossRef Yuan JM, Govindarajan S, Arakawa K, Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the US. Cancer. 2004;101(5):1009–177.CrossRef
7.
Zurück zum Zitat Koga H, Kai K, Aishima S, Kawaguchi A, Yamaji K, Ide T, et al. Occult hepatitis B virus infection and surgical outcomes in non-B, non-C patients with curative resection for hepatocellular carcinoma. World J Hepatol. 2017;9(35):1286–95.CrossRef Koga H, Kai K, Aishima S, Kawaguchi A, Yamaji K, Ide T, et al. Occult hepatitis B virus infection and surgical outcomes in non-B, non-C patients with curative resection for hepatocellular carcinoma. World J Hepatol. 2017;9(35):1286–95.CrossRef
8.
Zurück zum Zitat European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.CrossRef European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.CrossRef
9.
Zurück zum Zitat Fang Y, Shang QL, Liu JY, Li D, Xu WZ, Teng X, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009;58(5):383–8.CrossRef Fang Y, Shang QL, Liu JY, Li D, Xu WZ, Teng X, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009;58(5):383–8.CrossRef
10.
Zurück zum Zitat Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology. 2001;34(1):194–203.CrossRef Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology. 2001;34(1):194–203.CrossRef
11.
Zurück zum Zitat Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010;48(1):23–9.CrossRef Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010;48(1):23–9.CrossRef
12.
Zurück zum Zitat Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann of Surg. 2015;261(3):513–20.CrossRef Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann of Surg. 2015;261(3):513–20.CrossRef
13.
Zurück zum Zitat Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, et al. Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy. Med Oncol. 2013;30(4):721.CrossRef Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, et al. Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy. Med Oncol. 2013;30(4):721.CrossRef
14.
Zurück zum Zitat Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.CrossRef Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.CrossRef
15.
Zurück zum Zitat Itoh S, Yoshizumi T, Tomino T, Nagatsu A, Motomura T, Harada N, et al. Associations between antibody to hepatitis B core antigen positivity and outcomes in hepatocellular carcinoma patients undergoing hepatic resection. Hepatol Res. 2018;48(3):E155–E161161.CrossRef Itoh S, Yoshizumi T, Tomino T, Nagatsu A, Motomura T, Harada N, et al. Associations between antibody to hepatitis B core antigen positivity and outcomes in hepatocellular carcinoma patients undergoing hepatic resection. Hepatol Res. 2018;48(3):E155–E161161.CrossRef
16.
Zurück zum Zitat Li T, Wang SK, Zhou J, Sun HC, Qiu SJ, Ye QH, et al. Positive HBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of HBV-related HCC. Liver Int. 2016;36(2):284–92.CrossRef Li T, Wang SK, Zhou J, Sun HC, Qiu SJ, Ye QH, et al. Positive HBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of HBV-related HCC. Liver Int. 2016;36(2):284–92.CrossRef
17.
Zurück zum Zitat Omichi K, Shindoh J, Yamamoto S, Matsuyama Y, Akamatsu N, Arita J, et al. Postoperative Outcomes for Patients with Non-B Non-C Hepatocellular Carcinoma: A Subgroup Analysis of Patients with a History of Hepatitis B Infection. Ann Surg Oncol. 2015;22(Suppl 3):S1034–S10401040.CrossRef Omichi K, Shindoh J, Yamamoto S, Matsuyama Y, Akamatsu N, Arita J, et al. Postoperative Outcomes for Patients with Non-B Non-C Hepatocellular Carcinoma: A Subgroup Analysis of Patients with a History of Hepatitis B Infection. Ann Surg Oncol. 2015;22(Suppl 3):S1034–S10401040.CrossRef
18.
Zurück zum Zitat Coppola N, Onorato L, Sagnelli C, Sagnelli E, Angelillo IF. Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis. Medicine (Baltimore). 2016;95(30):e4311.CrossRef Coppola N, Onorato L, Sagnelli C, Sagnelli E, Angelillo IF. Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis. Medicine (Baltimore). 2016;95(30):e4311.CrossRef
19.
Zurück zum Zitat Hiwatashi K, Ueno S, Sakoda M, Iino S, Minami K, Yamasaki Y, et al. Problems of long survival following surgery in patients with NonBNonC-HCC: comparison with HBV and HCV Related-HCC. J Cancer. 2015;6(5):438–47.CrossRef Hiwatashi K, Ueno S, Sakoda M, Iino S, Minami K, Yamasaki Y, et al. Problems of long survival following surgery in patients with NonBNonC-HCC: comparison with HBV and HCV Related-HCC. J Cancer. 2015;6(5):438–47.CrossRef
20.
Zurück zum Zitat Sulpice L, Rayar M, Campillo B, Pery C, Guillaud A, Meunier B, et al. Advanced age remains an achilles heel for liver resections. World J Surg. 2014;38(4):918–26.CrossRef Sulpice L, Rayar M, Campillo B, Pery C, Guillaud A, Meunier B, et al. Advanced age remains an achilles heel for liver resections. World J Surg. 2014;38(4):918–26.CrossRef
21.
Zurück zum Zitat Nakai T, Koh K, Kawabe T, Shiraishi O, Okuno K, Yasutomi M. Clinical characteristics of hepatitis B core antibody-positive hepatocellular carcinoma. World J Surg. 2002;26(6):700–3.CrossRef Nakai T, Koh K, Kawabe T, Shiraishi O, Okuno K, Yasutomi M. Clinical characteristics of hepatitis B core antibody-positive hepatocellular carcinoma. World J Surg. 2002;26(6):700–3.CrossRef
22.
Zurück zum Zitat Nishikawa H, Osaki Y. Non-B, non-C hepatocellular carcinoma (Review). Int J Oncol. 2013;43(5):1333–422.CrossRef Nishikawa H, Osaki Y. Non-B, non-C hepatocellular carcinoma (Review). Int J Oncol. 2013;43(5):1333–422.CrossRef
23.
Zurück zum Zitat Wu ZF, Xu Z, Li WS, Zhang HB, Yang N, Yao XQ, et al. Impact of occult hepatitis B virus infection on outcome after resection for non-B non-C hepatocellular carcinoma. J Surg Res. 2015;193(1):153–60.CrossRef Wu ZF, Xu Z, Li WS, Zhang HB, Yang N, Yao XQ, et al. Impact of occult hepatitis B virus infection on outcome after resection for non-B non-C hepatocellular carcinoma. J Surg Res. 2015;193(1):153–60.CrossRef
24.
Zurück zum Zitat Wong DKH, Huang FY, Lai CL, Poon RTP, Seto WK, Fung J, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011;54(3):829–36.CrossRef Wong DKH, Huang FY, Lai CL, Poon RTP, Seto WK, Fung J, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011;54(3):829–36.CrossRef
25.
Zurück zum Zitat Lee SB, Kim KM, An J, Lee D, Shim JH, Lim YS, et al. Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int. 2016;36(9):1351–61.CrossRef Lee SB, Kim KM, An J, Lee D, Shim JH, Lim YS, et al. Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int. 2016;36(9):1351–61.CrossRef
26.
Zurück zum Zitat Yano Y, Yamashita F, Sumie S, Ando E, Fukumori K, Kiyama M, et al. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. Am J Gastroenterol. 2002;97(1):156–61.CrossRef Yano Y, Yamashita F, Sumie S, Ando E, Fukumori K, Kiyama M, et al. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. Am J Gastroenterol. 2002;97(1):156–61.CrossRef
27.
Zurück zum Zitat Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol. 2014;6(12):860–9.CrossRef Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol. 2014;6(12):860–9.CrossRef
28.
Zurück zum Zitat Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652–7.CrossRef Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652–7.CrossRef
29.
Zurück zum Zitat Inuzuka T, Ueda Y, Morimura H, Fujii Y, Umeda M, Kou T, et al. Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence. J Hepatol. 2014;61(3):492–501.CrossRef Inuzuka T, Ueda Y, Morimura H, Fujii Y, Umeda M, Kou T, et al. Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence. J Hepatol. 2014;61(3):492–501.CrossRef
30.
Zurück zum Zitat Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59–68.CrossRef Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59–68.CrossRef
Metadaten
Titel
Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma
verfasst von
Shan-Shan Wu
Quan-Yuan Shan
Wen-Xuan Xie
Bin Chen
Yang Huang
Yu Guo
Xiao-Yan Xie
Ming-De Lu
Bao-Gang Peng
Ming Kuang
Shun-Li Shen
Wei Wang
Publikationsdatum
06.06.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 3/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02141-8

Weitere Artikel der Ausgabe 3/2020

Clinical and Translational Oncology 3/2020 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.